Mustang Bio, Inc.
MBIOMustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for cancer and rare diseases. Established to leverage innovative scientific advancements, the company aims to deliver targeted treatments with the potential for durable responses in patients with unmet medical needs.
Company News
Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.
Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.
Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock, Series C-1 warrants, and Series C-2 warrants, raising approximately $8 million in gross proceeds.
Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announce...
Related Companies
